Search
for
Sort by
Research
210-240 / 1000+ results
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Ruxolitinib found to cause eyelash growth: a case report
Ruxolitinib treatment may cause eyelash growth.
research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Ruxolitinib cream may help treat severe hair loss in children.
research The Multidimensional Assessment of Interoceptive Awareness-2 Scale: A Turkish Validity and Reliability Study in Patients Admitted to the Dermatology Outpatient Clinic
The Turkish version of the MAIA-2 Scale is valid and reliable for patients at a dermatology clinic.
research Pioneers in Dermatology and Venereology: an interview with Professor Francisco Miguel Camacho Martinez
Francisco Camacho Martinez has made significant contributions to skin and sexually transmitted diseases, developed surgical techniques, but is concerned about patient survival rates and over-specialization in dermatology.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Calreticulin: non‐endoplasmic reticulum functions in physiology and disease
Calreticulin has roles in healing, immune response, and disease beyond its known functions in the endoplasmic reticulum.
research ERULUS Is a Plasma Membrane-Localized Receptor-Like Kinase That Specifies Root Hair Growth by Maintaining Tip-Focused Cytoplasmic Calcium Oscillations
ERULUS is crucial for root hair growth by controlling calcium levels.
research Cthrc1 deficiency aggravates wound healing and promotes cardiac rupture after myocardial infarction via non-canonical WNT5A signaling pathway
CTHRC1 is essential for healing and preventing heart rupture after a heart attack.
research 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research The Retinoic-Acid-Related Orphan Receptor Alpha May Be Highly Involved in the Regulation of Seasonal Hair Molting
RORA plays a key role in controlling seasonal hair molting by affecting hair follicle cell activity.
research A COMPARISON OF THE TOXICITIES OF 4-(ETHOXYCARBOPHENYL) RETINAMIDE AND SOME OTHER RETINOIDS
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
research Venus trap in the mouse embryo reveals distinct molecular dynamics underlying specification of first embryonic lineages
Tmem50b and 2610305D13Rik genes play key roles in early mouse embryo development.
research Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
Topical Ruxolitinib may safely treat severe hair loss.
research Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report
A man developed skin issues from cancer medication, which improved with specific treatments.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient
Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
research Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene
The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
research Igf1r signalling acts on the anagen‐to‐catagen transition in the hair cycle
Igf1r helps regulate hair growth cycles.
research [An infant with short stature and red cheeks (Rothmund-Thomson syndrome)].
The infant was diagnosed with Rothmund-Thomson syndrome, a rare genetic disorder causing various physical and developmental issues.